What is Medical Developments International Gross Margin %?
Medical Developments InternationalFRA:M5D +1.55%32 Gross Margin % is 73.47% as of Dec. 2025, which is 5% above its 10-year median of 70.13. GuruFocus rates FRA:M5D with a GF Score™ of 32/100 and a GF Value™ of €0.35 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 938 Drug Manufacturers companies, Medical Developments International ranks better than 88.17% on this metric.
Medical Developments International (FRA:M5D) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medical Developments International had a gross margin of 73.47% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medical Developments International Gross Margin % Related Terms
Medical Developments International Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International Gross Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medical Developments International's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medical Developments International (FRA:M5D) has a Gross Margin % of 73.47% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Medical Developments International and its competitors. This is near median its historical median of 70.13. Over the past decade, Medical Developments International's Gross Margin % has ranged from 64.95 to 75.57. According to the industry distribution chart, Medical Developments International ranks #111 out of 938 companies in the Drug Manufacturers industry, placing it in the top 11.8%.
Is Medical Developments International's Gross Margin % too high?
Medical Developments International's current Gross Margin % of 73.47% is near median its 10-year median of 70.13. Over the past 10 years, this metric has ranged from a low of 64.95 to a high of 75.57. The Drug Manufacturers industry median Gross Margin % is 48.44. Medical Developments International's value of 73.47% is 51.7% above this industry median. Based on the distribution chart, Medical Developments International ranks #111 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medical Developments International has a GF Score™ of 32/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #111 out of 938 companies for Gross Margin %. This places Medical Developments International in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.44. Medical Developments International's value of 73.47% is 51.7% above this benchmark. Historically, Medical Developments International's own Gross Margin % has ranged from 64.95 to 75.57 over the past decade. While the company's 10-year median is 70.13 vs. the industry median of 48.44, Medical Developments International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current Gross Margin % of 73.47% is 51.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current Gross Margin % is 73.47%, which is near median its own 10-year median of 70.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (FRA:M5D) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.35, compared to a current price of €0.20 — trading 43.7% below its estimated fair value. The current Gross Margin % is 73.47%, which is near median its 10-year median of 70.13 and 51.7% above the Drug Manufacturers industry median of 48.44. Medical Developments International's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medical Developments International (FRA:M5D), the current Gross Margin % is 73.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (FRA:M5D) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of €0.20 is trading 43.7% below its estimated GF Value™ of €0.35.
GuruFocus considers Medical Developments International to be Significantly Undervalued.
Key valuation signals for FRA:M5D:
Gross Margin %: 73.47% (near median its 10-year median of 70.13)
GF Value™: €0.35 vs. price of €0.20 (43.7% below fair value)
Industry Position: 51.7% above the Drug Manufacturers median (#111 of 938)
No single metric tells the full story. See the FRA:M5D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Business Description
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
32GF Score
Get the complete analysis for FRA:M5D
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M5D has been successfully added to your 
